CHICAGO – ARCH Venture Partners, one of the world’s leading early-stage technology venture firms, today announced the promotion of Corey Ritter to Partner.
“Corey’s contributions have been crucial to the growth and success of numerous ARCH portfolio companies. We look forward to seeing his continued impact in this new role as we work together to build the next generation of industry-leading companies,” said ARCH Co-founder and Managing Director Keith Crandell.
Ritter joined ARCH Venture Partners in 2018. Ritter is a Director at Slingshot Biosciences, Quantum Circuits, Elephas Biosciences, and Enumerix, and he co-founded other ARCH portfolio companies including Scale Biosciences and Vizgen. Prior to ARCH, Ritter was an associate with the University of Chicago Innovation Fund, a seed fund that supports and invests in scientific spinouts from the University of Chicago and Argonne National Lab. Previously, Ritter was an officer in the U.S. Army. He holds a B.A. in astrophysics from Princeton University and completed his M.B.A. at the University of Chicago.
In September, ARCH announced the closing of ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies.
About ARCH Venture Partners
ARCH Venture Partners creates and invests in groundbreaking life science and technology companies. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.
For more information, visit www.archventure.com.
Contact:
Morgan Warners
FGS Global
morgan.warners@fgsglobal.com